UMR 944 - 7212 – Equipe 7 - Translational cancer studies

Groheux D, Majdoub M, Sanna A, de Cremoux P, Hindié E, Giacchetti S, Martineau A, de Roquancourt A, Merlet P, Visvikis D, Resche-Rigon M, Hatt M, Espié M. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype. Radiology. 2015 Nov;277(2):358-71. 

Bally C, Renneville A, Preudhomme C, Legrand M, Adès L, de Thé H, Fenaux P, Lehmann-Che J. Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next generation sequencing in myelodysplastic syndromes. Leuk Res. 2015 Jul 4

Amelot A, de Cremoux P, Quillien V, Polivka M, Adle-Biassette H, Lehmann-Che  J, Françoise L, Carpentier AF, George B, Mandonnet E, Froelich S. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients. PLoS One. 2015 Jul 9;10(7):e0130596

Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, Espié M, Merlet P, de Roquancourt A, Visvikis D, Hatt M, Resche-Rigon M, Hindié E. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer. J Nucl Med. 2015 Jun;56(6):824-31. 

Chirica M, Le Bourhis L, Lehmann-Che J, Chardiny V, Bouhidel F, Foulboeuf L,  Gornet JM, Lourenco N, Dulphy N, Toubert A, Allez M. Phenotypic analysis of T cells infiltrating colon cancers: Correlations with oncogenetic status. Oncoimmunology. 2015 Apr 1;4(8)

de Cremoux P, Dalvai M, N'Doye O, Moutahir F, Rolland G, Chouchane-Mlik O, Assayag F, Lehmann-Che J, Kraus-Berthie L, Nicolas A, Lockhart BP, Marangoni E, de Thé H, Depil S, Bystricky K, Decaudin D. HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts. Breast Cancer Res Treat. 2015 Jan;149(1):81-9.

Bellocq JP, Luporsi E, Barrière J, Bonastre J, Chetritt J, Le Corroller AG, de Crémoux P, Fina F, Gauchez AS, Kassab-Chahmi D, Lamy PJ, Martin PM, Mazouni C, Peyrat JP, Romieu G, Verdoni L, Mazeau-Woynar V. [uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management]. Ann Pathol. 2014 Oct;34(5):349-51.

Gauthier H, Douchet G, Lehmann-Che J, Meignin V, Raynaud C, Sabatier P, de Cremoux H, Poirot B, Culine S, Pouessel D, de Cremoux P. Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy. J Thorac Oncol. 2014 Oct;9(10):e78-9

Lehmann-Che J, Bally C, de Thé H.  Resistance to therapy in acute promyelocytic leukemia. N Engl J Med. 2014 Sep 18;371(12):1170-2.

Groheux D, Hindié E, Giacchetti S, Hamy AS, Berger F, Merlet P, de Roquancourt A, de Cremoux P, Marty M, Hatt M, Espié M. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help  predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. Eur J Cancer. 2014 Jul;50(11):1864-71. 

Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme C, Mozziconacci MJ, de The H, Lehmann-Che J, Fenaux P. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk Res. 2014 Jul;38(7):751-5

Dohan A, Lousquy R, Eveno C, Goere D, Broqueres-You D, Kaci R, Lehmann-Che J, Launay JM, Soyer P, Bonnin P, Pocard M. Orthotopic animal model of pseudomyxoma peritonei: An in vivo model to test anti-angiogenic drug effects. Am J Pathol. 2014 Jul;184(7):1920-9

Győrffy B, Bottai G, Lehmann-Che J, Kéri G, Orfi L, Iwamoto T, Desmedt C, Bianchini G, Turner NC, de Thè H, André F, Sotiriou C, Hortobagyi GN, Di Leo A, Pusztai L, Santarpia L. TP53 mutation-correlated genes predict the risk of tumor  relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. Mol Oncol. 2014 May;8(3):508-19

Laroche F, Coste J, Medkour T, Cottu PH, Pierga JY, Lotz JP, Beerblock K, Tournigand C, Declèves X, de Cremoux P, Bouhassira D, Perrot S. Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study. J Pain. 2014 Mar;15(3):293-303. 

Dumont C, Gauthier H, Vérine J, Lehmann-Che J, de Cremoux P, Pouessel D, Culine S. Concomitant bifocal urothelial carcinoma and breast tumor: second primary cancer or metastatic spread to the breast? Case Rep Oncol Med. 2014;2014:917581.

Giacchetti S, Porcher R, Lehmann-Che J, Hamy AS, de Roquancourt A, Cuvier C, Cottu PH, Bertheau P, Albiter M, Bouhidel F, Coussy F, Extra JM, Marty M, de Thé  H, Espié M. Long-term survival of advanced triple-negative breast cancers with a  dose-intense cyclophosphamide/anthracycline neoadjuvant regimen. Br J Cancer. 2014 Mar 18;110(6):1413-9.

Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B,  Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranel J. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014 Jan;25(1):126-31. 

Beau-Faller M, Blons H, Domerg C, Gajda D, Richard N, Escande F, Solassol J, Denis MG, Cayre A, Nanni-Metellus I, Olschwang S, Lizard S, Piard F, Pretet JL, de Fraipont F, Bièche I, de Cremoux P, Rouquette I, Bringuier PP, Mosser J, Legrain M, Voegeli AC, Saulnier P, Morin F, Pignon JP, Zalcman G, Cadranel J. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1:Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms. J Mol Diagn. 2014 Jan;16(1):45-55. 

Valet F, de Cremoux P, Spyratos F, Servant N, Dujaric ME, Gentien D, Lehmann-Che J, Scott V, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Delaloge S, Giacchetti S, Brain E, Tembo O, Marty M, Asselain B. Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial. Breast. 2013 Dec;22(6):1052-9.

Laroche F, Coste J, Medkour T, Cottu PH, Pierga JY, Lotz JP, Beerblock K, Tournigand C, Declèves X, de Cremoux P, Bouhassira D, Perrot S. Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicentre cohort study. J Pain. 2013 Dec 20. pii: S1526-5900(13)01421-1.

Richard R, Thomassin I, Chapellier M, Scemama A, de Cremoux P, Varna M, Giacchetti S, Espié M, de Kerviler E, de Bazelaire C. Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol. 2013 Sep;23(9):2420-31 

Roca L, Diéras V, Roché H, Lappartient E, Kerbrat P, Cany L, Chieze S, CanonJL, Spielmann M, Penault-Llorca F, Martin AL, Mesleard C, Lemonnier J, de Cremoux P. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial. Breast Cancer Res Treat. 2013 Jun;139(3):789-800. 

Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J,Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D,Espié M. Estrogen receptor-positive/human epidermal growth factor receptor2-negative breast tumors: early prediction of chemosensitivity with(18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. Cancer. 2013 Jun 1;119(11):1960-8. 

Cizkova M, Dujaric ME, Lehmann-Che J, Scott V, Tembo O, Asselain B, Pierga JY,Marty M, deCremoux P, Spyratos F, Bieche I. Outcome impact of PIK3CA mutationsin HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer.2013 May 14;108(9):1807-9.. 

Lehmann-Che J, Hamy AS, Porcher R, Barritault M, Bouhidel F, Habuellelah H,Leman-Detours S, de Roquancourt A, Cahen-Doidy L, Bourstyn E, de Cremoux P, deBazelaire C, Albiter M, Giacchetti S, Cuvier C, Janin A, Espié M, de Thé H,Bertheau P. Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res. 2013May 11;15(3):R37. 

Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I, Penault-Llorca F. SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer. 2013 Jul 22;13:351. doi:10.1186/1471-2407-13-351.

Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L,Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ,Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I,Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A,Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I,Penault-Llorca F. SISH/CISH or qPCR as alternative techniques to FISH fordetermination of HER2 amplification status on breast tumors core needle biopsies:

Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M, de Thé H. p53 in breast cancer subtypes and new insights into response to chemotherapy. Breast. 2013 Aug;22 Suppl 2:S27-9. 

Valet F, de Cremoux P, Spyratos F, Servant N, Dujaric ME, Gentien D, Lehmann-Che J, Scott V, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Delaloge S, Giacchetti S, Brain E, Tembo O, Marty M, Asselain B. Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: Experience of the REMAGUS 02 phase II trial. Breast. 2013 Dec;22(6):1052-9 

Sylvia Julien, Ana Merino-Trigo, Ludovic Lacroix, Marc Pocard, Diane Goéré, Pascale Mariani, Sophie Landron, Ludovic Bigot, Fariba Nemati, Peggy Dartigues, Louis-Bastien Weiswald, Denis Lantuas, Loïc Morgand, Emmanuel Pham, Patrick Gonin, Virginie Dangles-Marie, Bastien Job, Philippe Dessen, Alain Bruno, Alain Pierré, Hugues de Thé, Hany Soliman, Manoel Nunes, Guillaume Lardier, Loreley Calvet, Brigitte Demers, Grégoire Prévost, Patricia Vrignaud, Sergio Roman-Roman, Olivier Duchamp, Cyril Berthet .(2012) Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.Clin Cancer Res. 2012 Oct 1;18(19):5314-28 

Anne Dumay, Jean-Paul Feugeas, Evelyne Wittmer, Jacqueline Lehmann-Che, Philippe Bertheau, Marc Espié, Louis-François Plassa, Paul Cottu, Michel Marty, Fabrice André, Christos Sotiriou, Lajos Pusztai and Hugues de Thé (2012) Distinct TP53 mutants in breast cancers subgroups. Int J Cancer, 2013 Mar 1;132(5):1227-31. 

Luporsi E, André F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B, Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D, Spielmann M, Haugh M, Chenard MP, Brain E, de Cremoux P, Bellocq JP (2012). Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat. 2012 Apr;132(3):895-915 

Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F, Bonnet F, Martin AL, Feugeas JP, Bièche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci F, de Thé H, Theillet C (2012). A refined molecular taxonomy of breast cancer. Oncogene. Mar 1;31(9):1196-206. 

Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, de Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E. (2012) Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. Jan 16;14(1):R11. 

Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader Ch, de Plater L, Elbaz C, Karboul N, Fontaine JJ, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D.(2012) Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. Breast Cancer Res Treat. Jun;133(2):595-606 

-Spyratos F, Valet F, Bièche I, Scott V, Lehmann-Che J, Asselain B, Tembo O, Marty M, de Cremoux P (2011). Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer. Breast Cancer Res Treat. Apr 12., 132: 443-448 

Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de Thé H, Pusztai L.(2011) Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res. Apr 15;17(8):2591-601. 

Lehmann-Che J, Amira-Bouhidel F, Turpin E, Antoine M, Soliman H, Legres L, Bocquet C, Bernoud R, Flandre E, Varna M, de Roquancourt A, Plassa LF, Giacchetti S, Espié M, de Bazelaire C, Cahen-Doidy L, Bourstyn E, Janin A, de Thé H, Bertheau P. (2011) Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches. Br J Cancer. May 24;104(11):1739-46. 

Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, de Roquancourt A, Hamy AS, Cuvier C, Vercellino L, Hindié E. (2011) Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging Mar;38(3):426-35 

de Cremoux P, Valet F, Gentien D, Lehmann-Che J, Scott V, Tran-Perennou C, Barbaroux C, Servant N, Vacher S, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Asselain B, Marty M, Spyratos F.(2011) Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients. BMC Cancer. Jun 1;11:215. 

de Plater L, Laugé A, Guyader C, Poupon MF, Assayag F, de Cremoux P, Vincent-Salomon A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fontaine JJ, Brough R, Lord CJ, Ashworth A, Cottu P, Decaudin D, Marangoni E. (2010) Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer. Oct 12;103(8):1192-200. 

Lehmann-Che J, André F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espié M, Plassa LF, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, de Thé H. (2010) ;Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist. 15(3):246-52. 

Bollet MA, Savignoni A, De Koning L, Tran-Perennou C, Barbaroux C, Degeorges A, Sigal-Zafrani B, Almouzni G, Cottu P, Salmon R, Servant N, Fourquet A, de Cremoux P (2009). Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment. Breast Cancer Res.;11(4):R54. 

Varna M, Lehmann-Che J, Turpin E, Marangoni E, El-Bouchtaoui M, Jeanne M, Grigoriu C, Ratajczak P, Leboeuf C, Plassa LF, Ferreira I, Poupon MF, Janin A, de Thé H, Bertheau P. (2009) p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. Int J Cancer. Feb 15;124(4):991-7. 

Manié E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, Gruel N, Lebigot I, Sastre-Garau X, Lidereau R, Remenieras A, Feunteun J, Delattre O, de Thé H, Stoppa-Lyonnet D, Stern MH. (2009) High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res. Jan 15;69(2):663-71. Erratum in: Cancer Res. 2009 Apr1;69(7):3240.

Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ 2nd, de Cremoux P, Stenvang J, Lykkesfeldt AE (2009). Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat. Mar;114(2):263-75. 

Varna M, Soliman H, Feugeas JP, Turpin E, Chapelin D, Legrès L, Plassa LF, de Roquancourt A, Espié M, Misset JL, Janin A, de Thé H, and Bertheau P (2007) Changes in allelic imbalances in locally advanced breast cancers after chemotherapy. Br J Cancer 97, 1157–1164. 

Legrier ME, Oudard S, Judde JG, Guyader C, de Pinieux G, Boyé K, de Cremoux P, Dutrillaux B, Poupon MF (2007). Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer. Jan 29;96(2):269-76. 

Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, Longy M, Raynal V, Pierron G, de Mascarel I, Taris C, Stoppa-Lyonnet D, Pierga JY, Salmon R, Sastre-Garau X, Fourquet A, Delattre O, de Cremoux P, Aurias A (2007). Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res.;9(2):R24. 

Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Diéras V, Poupon MF (2007). A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. Jul 1;13(13):3989-98. 

Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H. (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med. Mar;4(3):e90